# Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

> **NCT00563108** · NA · UNKNOWN · sponsor: **Hospital Authority, Hong Kong** · enrollment: 60 (estimated)

## Conditions studied

- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Basiliximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00563108
- **Lead sponsor:** Hospital Authority, Hong Kong
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2010-07-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563108, "Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00563108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*